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ORIGINAL ARTICLE
Quality of life valuations of HPV-associated cancer
health states by the general population
E Lynne Conway,1 K Chip Farmer,2 William J Lynch,3 Guy L Rees,4 Gerard Wain,5
Jane Adams6
ABSTRACT
Objectives To obtain health-related quality of life
valuations (ie, utilities) for human papillomavirus (HPV)-
related cancer health states of vulval, vaginal, penile,
anal and oropharyngeal cancers for use in modelling
cost-effectiveness of prophylactic HPV vaccination.
Methods Written case descriptions of each HPV-
associated cancer describing the ‘average’ patient
surviving after the initial cancer diagnosis and treatment
were developed in consultation with oncology clinicians.
A general overview, standard gamble questionnaire for
each health state and a quiz was conducted in 120
participants recruited from the general population.
Results In the included population sample (n¼99), the
average age was 43 years (range ¼ 18e70 years) with
54% men, 44% never married/43% married, 76%
education beyond year 12 and 39% employed full-time.
The utility values for the five health states were 0.57
(95% CI 0.52 to 0.62) for anal cancer, 0.58 (0.53 to 0.63)
for oropharyngeal cancer, 0.59 (0.54 to 0.64) for vaginal
cancer, 0.65 (0.60 to 0.70) for vulval cancer and 0.79
(0.74 to 0.84) for penile cancer. Participants
demonstrated a very good understanding of the
symptoms, diagnosis and treatment of these cancers
with a mean score of 9 (SD¼1.1) on a 10-item quiz.
Conclusions This study provides utility estimates for the
specific HPV-related cancers of vulval, vaginal, penile,
anal and oropharyngeal cancers valued by a general
population sample using standard gamble. The results
demonstrate considerable quality of life impact
associated with surviving these cancers that will be
important to incorporate into modelling cost-
effectiveness of prophylactic HPV vaccination in different
populations.
INTRODUCTION
Human papillomavirus (HPV) is one of the most
common sexually transmitted infections, with
more than 50% sexually active persons becoming
infected with one or more types.1 In most cases,
infection clears without sequelae but high-risk
types are now accepted as a necessary cause of all
cervical cancers (predominantly HPV types 16, 18)
and low-risk types cause genital warts (predomi-
nantly HPV 6, 11) in both genders. With the
registration of the quadrivalent (HPV types 16, 18,
6, 11) and bivalent (HPV types 16, 18) vaccines in
2006, many countries have introduced population-
level vaccination programmes of young pre-sexu-
ally active women with the aim of preventing
cervical precancerous lesions/cancer and genital
warts. In many countries, including the USA,
Europe, Australia and New Zealand, this decision
making incorporated an assessment of cost-utility,
comparing the incremental costs and beneﬁts in
survival and health-related quality of life in vacci-
nated and unvaccinated populations, with the
beneﬁts expressed as quality-adjusted life years.2
There is now substantial evidence that the HPV
also causes a signiﬁcant proportion of cancers of the
vulva, vagina, penis, anus and oral cavity and
oropharynx and that prophylactic vaccination
prevents high-grade HPV 16, 18 precancerous ano-
genital lesions in women and men.3 Modelling of
the cost-utility of introducing or extending HPV
vaccination programmes to these populations
requires examination of the incremental costs
and quality-adjusted life years of vaccination
programmes on the full extent of HPV disease.
Although health state valuations appropriate for
modelled economic evaluations have been under-
taken for cervical HPV disease including cancer and
precancerous lesions,4 5 and for genital warts,6 there
is a paucity of information on health state valua-
tions for the other HPV cancer states.7 Studies that
have assigned utility values to non-cervical HPV-
related cancers use a generic ‘female genital cancer ’
as a proxy for all the cancer health states.7 In this
study, we obtain health-related quality of life
valuations for ﬁve health states representative
of the average patient surviving with anal,
oropharyngeal, penile, vulval and vaginal cancers.
METHODS
Health states
We sought to identify health states related to each
cancer that were of signiﬁcant duration and
frequency to be useful for modelling prevention
strategies for HPV-associated cancers. We focused
on the longer term health state that would apply to
the majority of patients for the period starting after
the initial treatment effects had resolved out to
5 years after diagnosis. After an initial literature
review and discussion with clinical experts, we
concluded that the morbidity of the longer term
health state is related mainly to the treatment
modality, which is itself usually determined by the
location and stage of the cancer at diagnosis. The
process for developing the health states therefore
involved the following steps (1) the most common
stage(s) of each of the HPV-associated cancers on
diagnosis were identiﬁed from the literature, (2) the
recommended treatment for the relevant stages(s)
of each cancer was identiﬁed and conﬁrmed from
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published studies and (3) the more common long-term conse-
quences (applying to $50% patients) in patients surviving the
initial treatment phase were described based on the literature
and subsequent reﬁnement by clinical experts involved in
managing each cancer. For each of the HPV-associated cancers,
we were able to identify a single health state to describe the
‘typical’ patient surviving after the initial cancer diagnosis and
treatment.
As the initial treatment leads to the long-term health state,
a brief description of the treatment was included as background
but speciﬁed as not for valuation.
A presentation on HPV and its role in the development of
cancer, the risk factors for HPV-associated cancers and an over-
view of each cancer including initial symptoms, staging, treat-
ment and long-term survival was developed to introduce the
topic in the health state valuation sessions.
Study population
Subjects from the general population were recruited through an
external market research company and paid an honorarium of
$70. The enrolment criteria included age 18 years or older and
ﬂuency in English sufﬁcient to complete a reasonably compli-
cated questionnaire. Participants were also to comprise a mix of
currently employed and unemployed. Exclusion criteria included
participation in a valuation study in the previous 6 months,
employment in a health-related occupation or pharmaceutical
company and current participation in a clinical trial.
Health state valuation
Participants attended an hour long session in groups of 30. The
presentation was undertaken by a trained presenter, and the
study questionnaire was completed by the participants in small
groups. Each group had a trained group leader who was available
to answer questions throughout. The questionnaire comprised
ﬁve sections including demographics, experience of HPV-related
cancers, understanding of HPV-related cancers in a quiz format,
a practice scenario and utility valuation of the ﬁve health states
using a direct standard gamble methodology.
The presentation and questionnaire were initially trialled in
30 participants. As participants handled the complexity of the
questionnaire well and demonstrated good understanding of the
background information, no changes were made. Participants
also reported that the background treatment information (not
for valuation) was important for valuing the long-term health
state; this information was included in all subsequent testing.
The study was completed by a further 90 participants. The
combined results are presented.
For each health state, participants were told to imagine they
had been diagnosed and treated for anal, oropharyngeal, vaginal,
vulvar and penile cancers. They were asked to consider how
being in that health state would impact on their ability to
participate in their usual activities such as work, social activities
and caring roles; their independence; whether they would still be
able to do things without the help of others; their social inter-
actions and how they would feel about these changes. For the
standard gamble valuation, participants were asked to choose
between living in the health state for the rest of their life or
taking a gamble. Probabilities for the gamble were presented in
a ping pong fashion starting at 100% chance of perfect health
followed by 100% chance of death, then 90% chance of perfect
health/10% chance of death followed by 10% chance of
perfect health/90% chance of death (see online technical
appendix for full questionnaire). The utility score was the
gamble probability at the point where the participant was
indifferent to taking the gamble or living in the health state.
Each participant was presented with the ﬁve health states in
a random order to prevent cognitive overload at the same stage
of the questionnaire and to prevent the possibility of an order
effect.
Statistical analysis
The demographic data, experience with the health states data
and quiz scores are analysed using descriptive statistics. The
standard gamble results for each health state are reported as the
utility score (mean, 95% CI; median, IQR). Responses from
irrational traders (where answers to two or more scenarios were
inconsistentdeg, chose a 40% risk of death but later would not
accept a 10% risk of deathdor illogicaldeg, chose to live in the
disease state rather than 100% chance of perfect health) and
non-traders (identical responses across all health states) were
excluded.
The impact of demographic characteristics on the utility
values were assessed using the KruskaleWallis test for categor-




For each HPV-associated cancer, a single health state was
developed that applied to the majority of patients diagnosed as
having the relevant cancer (table 1). Long-term health conse-
quences were related to the most common treatments for the
relevant stages. Less common debilitating and disﬁguring side
effects of treatment were omitted. The full health state
descriptions are presented in the online technical appendix.
Utility valuation
Completed questionnaires were received from 118 participants.
Of these, ﬁve were excluded because of irrational trading and 14
were excluded because of non-trading. Demographic informa-
tion for participants included in the analysis is summarised in
table 2. The average age was 43 years (range 18e70 years; SD
16). They represented a broad cross section of age, education
level, employment status and income and were evenly matched
by gender. No participants had been diagnosed as having any
of the HPV-associated cancers but several had experience
with a family member (2%) or a friend or acquaintance (16%)
diagnosed as having one of the cancers.
Results from the 10-question true/false style quiz demon-
strated that participants had a very good understanding of the
symptoms, diagnosis and treatment of these cancers following
the information presented at the beginning of the session
with a mean score of 9.14 (SD¼1.06; median 9; range 5e10).
Participants had no appreciable difﬁculties with the standard
gamble questionnaire and all ﬁnished the task ahead of the
scheduled time.
The utility values for the ﬁve health states are presented in
table 3. The estimates were very similar for the oropharyngeal,
anal, vulval and vaginal cancer health states. The utility value
for the penile cancer health state was signiﬁcantly higher than
for the other cancer health states.
None of the demographic variables, including gender, had any
inﬂuence on the health state utility score (data not shown).
DISCUSSION
This study is the ﬁrst to provide estimates of health state
preferences for the speciﬁc HPV-related cancers of the vulval,
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vaginal, penile, anal and oropharyngeal. The study focused on
valuing the long-term health state of the average patient
surviving through to 5 years after diagnosis and treatment which
is the most appropriate state for modelling cost-effectiveness of
prophylactic vaccination. Because of the long interval between
vaccination and disease, modelling will not be sensitive to
short-term health states.
The health states reﬂect current treatment practices of each of
the HPV-related cancers taking into account the usual stage of
diagnosis for the particular cancer and recommended and actual
treatment practices. The health states were derived from the
literature and reviewed and reﬁned by clinical experts involved in
managing each cancer.
The utility valuations for the anogenital cancers other than
penile cancer were similar, varying from 0.57 for anal cancer,
0.59 for vaginal cancer and 0.64 for vulval cancer with over-
lapping CIs. Symptoms varied for each health state but included
one or more of compromised sexual functioning, bowel and
bladder irritation, loss of fertility and reduced general health.
Anal cancer is now primarily treated with radiotherapy and
the number of patients undergoing abdominoperitoneal resec-
tion is very low.9 Nonetheless, radiotherapy results in long-term
impacts on bowel and bladder function, sexual function and
physical and social functioning.17 Although not directly
comparable, the utility estimate for anal cancer in this study is
within the range of estimates for colorectal cancer without
ostomy using a similar methodology.18
Table 1 Cancer stages at diagnosis, primary treatment modalities and corresponding long-term health state descriptions*
Cancer
Stage at diagnosis and
primary treatment
Health state descriptions
Not includedCancer stage and treatment
Long-term health state in ‡50%
patients and patient follow-up for
5 years from primary treatment
Anal 90% Cases stages IeIII.8
Chemoradiation is the only
primary treatment for
anal cancer.9
Anal cancer stages IeIII.
Treated with chemoradiation.
Diarrhoea, tiredness and nausea;
impact on usual activities; decreased
sexual functioning and enjoyment.
Review 2e3 times per year (digital
rectal examination and anoscopy).
Stage IV. Patients with
abdominoperitoneal resection
and stoma. Patients treated
with surgical excision.
Oropharyngeal 90% Cancers present as
stage II/III.10 Most patients
have surgery followed by
radiotherapy.11 y
Oropharyngeal cancer
stages IIeIII. Treated with
neck dissection and chemotherapy
and/or radiotherapy and/or surgery.
Occasional pain; difficulty chewing
and swallowing affecting diet/eating;
dry throat affecting speech; reduced
neck mobility; tiredness; impact on
usual activities.
Review 2e3 times per year.
Stage I and stage IV. Disfiguring
effects of surgery. Patients who
require feeding tubes.
Penile 62% Cases local12; 70%
penile-preserving treatment
is laser therapy.13
Penile cancer stage I. Treated
with laser therapy onlydno
disfigurement.
Recovered well and satisfied with
surgery; no impairment of sexual
functioning/satisfaction.
Frequent self-inspection and
review 2e4 times per year.
Stages IIeIV. Patients requiring
partial or complete penectomy.
Vulval w66% Vulval cancers are
localiseddpredominantly
stages IeII.14 Treatment is
radical wide excision where
possible + lymph node
dissection.14
Vulval cancer stage I. Treated
with radical wide excision and
lymph node dissection.
Vigilance because of risk of
lymphoedema; clitoris intact and
can still reach orgasm but reduced
sexual satisfaction because of
disfigurement.
Review 2e3 times per year.




Vaginal w50% cases localisedd
predominantly stage 1.15
Radiotherapy + lymph node
dissection is standard
treatment.16
Vaginal cancer stage I. Treated
with chemoradiation and lymph
node dissection.
Vigilance because of risk of
lymphoedema; menopause; sexual
problems related to vaginal dryness
and scar tissue; bowel and bladder
irritation.
Review 2e3 times per year
(vaginal exam).
Stages IIeIV.
*Full details in online technical appendix.
yData on 548 patients with stage IeIV oropharyngeal squamous cell carcinoma from 10 Australian centres: 55.8% surgery followed by postoperative radiotherapy, 18.9% chemoradiation,
10.8% surgery alone and 14% radiotherapy alone (A Hong, personal communication).











Never married 44 44
Widowed/divorced/separated 12 12
Married/de facto 43 43
Highest level of education attained
Tertiary education 76 77
Secondary education 21 21
Primary education 2 2
Employment
Full time 39 39





$1600 or more per week 28 28
$800e1599 28 28
$1e799 40 40
Nil income 3 3
*Due to rounding, percentages may not total 100%.
Table 3 Utility scores for the five health states
Scenario N Mean (95% CI) Median (IQR)
Anal cancer 95 0.57 (0.52 to 0.62) 0.65 (0.45e0.75)
Oropharyngeal cancer 99 0.58 (0.53 to 0.63) 0.65 (0.45e0.75)
Vaginal cancer 98 0.59 (0.54 to 0.64) 0.65 (0.45e0.75)
Vulvar cancer 98 0.65 (0.60 to 0.70) 0.65 (0.45e0.85)
Penile cancer 97 0.79 (0.74 to 0.84) 0.85 (0.65e1.0)
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The treatment of vaginal cancer is very similar to that of
cervical cancer involving radiotherapy and chemotherapy.
Although there has been very little published on the quality of
life impacts of vaginal cancer, the long-term side effects are
similar to those of cervical cancer and include early menopause,
a narrower, drier and less stretchy vagina, risk of lymphoedema
and impact on bladder and bowel function. The utility estimate
for vaginal cancer from this study are within the range of esti-
mates reported for cervical cancer. Howard et al4 reported
a standard gamble-derived utility of 0.46 for cervical cancer in
an Australian population. Myers et al5 reported time trade-
off-derived utility of 0.76 and 0.67 for stages I and IIeIV cervical
cancer, respectively.
Vulval cancer is relatively rare, and there are few studies
exploring the impact on quality of life. It differs from the other
female gynaecological cancers because the primary treatment
modality (surgical excision) directly affects body image and
sexuality. Treatment of vulval cancer has been reported to have
a major negative impact on sexual functioning and body image
and on emotional, physical and social functioning.19 20
The health state valuation for penile cancer (0.75) was higher
than the other cancers. This corresponds with this health state
being the mildest, describing stage I penile cancer treated with
laser therapy and with no long-term consequences on general
health, sexual functioning or sexuality. This reﬂects that
approximately 60% penile cancer patients receive penile-
preserving treatments.13 It does not capture the health state of
patients undergoing partial or complete penectomy. These more
mutilating interventions have been reported to have a major
impact on sexual function and sexual satisfaction.21
The health state valuation for oropharyngeal cancer was
similar to that of anal and vaginal cancers. Head and neck cancer
has been described as more emotionally traumatic than any
other form of cancer.22 The treatments are debilitating and
disﬁguring, and patients often go on to live with chronic func-
tional impairment in a range of areas including speech and
swallowing as well as effects on oral health and nutrition.22e25
These changes are reﬂected in health-related quality of life where
there is an immediate decrease on treatment that lasts for
months.22 There is also evidence of long-term decrements in
health-related quality of life25 although these studies are
complicated by survivorship effects and a lack of sensitivity of
the instruments.22 In this study, the general population assess-
ment of the utility of the oropharyngeal cancer survivor is
similar to that of the female genital cancers.
A strength of this study is that it used the preferences of the
general population. There is a general consensus in the literature,
including a recommendation from the US Panel on Cost-effec-
tiveness in Health and Medicine, that where valuations are for
use in decision making around resource allocation, preferences
should be based on the general population in their role as
taxpayers rather than caregivers or patients.26 This is also
particularly appropriate for prophylactic vaccine programmes
where the target population is the well population.
This study also used the standard gamble to value health states.
Compared with rating scales or time trade-off, the standard
gamble has a solid foundation in the economic theory underlying
the use of utility as a measure for quality of life in cost-utility
analysis.27 Although standard gamble can be difﬁcult for partici-
pants to understand, the study was well received with partici-
pants handling the complexity of the questionnaire well. The quiz
scores show a good understanding of the presentation and the
information provided. Few participants were removed from the
analysis for either unusable answers or for irrational responses.
There are several limitations of this study. The health state
scenarios were developed from the literature and from oncology
experts in each cancer, not directly from patient interviews.
However, both the literature and the expert opinion are derived
from studies of patient-reported outcomes and reﬂect the
experience of patients. Also, the approach taken avoids the
difﬁculties that can arise from evaluations of health state pref-
erences of cancer survivors. Dropouts (death or loss to follow-
up), adaptation and response shift are known to inﬂuence
quality of life estimates in cancer survivors.22 28 These effects
may lead to a bias against preventive therapies. Another limi-
tation is the restriction to a single average health state for each
cancer. The health state descriptions represented the most
common stages and treatment pathways for cancer survivors
and as such contribute most to modelling the impact of
preventive measures. Although less common side effects of
treatment were omitted, either more severe and debilitating or
milder side effects, these would probably not affect model
conclusions. Similarly, the short duration health states related to
acute treatment phases were not included. Finally, respondents
in the study were Australians and hence may not be general-
isable to populations from other countries. Utility values have
been shown to vary across countries.29 30 Relative to UK
respondents, using standard gamble, Australians reported
a lower impact of less severe clinical response states in advanced
melanoma and a greater impact of the more severe response
states, although the differences were relatively small.29 In
modelling studies, this issue could be addressed with sensitivity
analyses.
CONCLUSIONS
The results of this study represent a signiﬁcant addition to the
literature of HPV-related cancer utility values. It is the ﬁrst
study to provide estimates of health state preferences for the
speciﬁc HPV-related cancers of the vulval, vaginal, penile anal
and oropharyngeal. The scenarios focused on the long-term
health state of the average patient from resolution of the acute
effects of treatment out to 5 years after diagnosis and treatment
and were valued by the general population. These valuations can
be incorporated into modelling cost-effectiveness of prophylactic
HPV vaccination in different populations.
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Key messages
< Estimates of the impact on quality of life (utilities) of HPV-
related cancers are needed for economic evaluations
comparing HPV vaccination strategies in men and women.
< This study determined utility valuations of life post-treatment
for the average patient with cancer of the anus, vulva, vagina,
penis and oropharynx.
< All cancers had a significant impact with utility values
between 0.57 and 0.79 compared with a perfect health utility
of 1.
Health services research
520 Sex Transm Infect 2012;88:517–521. doi:10.1136/sextrans-2011-050161
 group.bmj.com on February 3, 2013 - Published by sti.bmj.comDownloaded from 
Funding This study was funded by CSL Biotherapies, a subsidiary of CSL Limited. CSL
Limited is a financial beneficiary of sales of Gardasil and Cervarix; CSL Biotherapies
distributes Gardasil in Australia and New Zealand.
Competing interests ELC is an employee of CSL Biotherapies and also owns shares
in CSL Limited. JA is an employee of Pretium, a consultancy engaged by CSL
Biotherapies to undertake the study. GW has been involved in the research studies for
Gardasil and has acted as a consultant and received honoraria for speaking from
Merck and CSL Biotherapies. He received no financial compensation for this study.
WJL has acted as a consultant for CSL Biotherapies. He received no financial
compensation for this study.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections 3.
J Clin Virol 2005;32(Suppl 1):S16e24.
2. Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus
vaccination policy. Sex Health 2010;7:352e8.
3. Moscicki AB. Human papillomavirus disease and vaccines in adolescents. Adolesc
Med State Art Rev 2010;21:347e63, x-xi.
4. Howard K, Salkeld G, McCaffery K, et al. HPV triage testing or repeat Pap smear for
the management of atypical squamous cells (ASCUS) on Pap smear: is there
evidence of process utility? Health Econ 2008;17:593e605.
5. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV
infection: visual analog scales vs time trade-off elicitation. Proceedings of 21st
International Papillomavirus Conference. Mexico City, Mexico, 2004. Abstract 542.
6. Woodhall SC, Jit M, Soldan K, et al. The impact of genital warts: loss of quality of
life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect
2011;87:458e63.
7. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human
papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884.
8. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human
papillomavirus-associated anal cancers in the US. Cancer 2008;113:2892e900.
9. Bilimoria KY, Bentrem DJ, Ko CY, et al. Squamous cell carcinoma of the anal canal:
utilization and outcomes of recommended treatment in the United States. Ann Surg
Oncol 2008;15:1948e58.
10. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human
papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-
2003. Cancer 2008;113:2901e9.
11. NCCN Clinical Practice Guidelines in OncologydHead and Neck Cancers.
National Comprehensive Cancer Network. 2010. http://www.nccn.org/professionals/
physician_gls/PDF/head-and-neck.pdf (accessed Mar 2010).
12. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell
carcinoma of the penis in the United States, 1998-2003. Cancer 2008;113:2883e91.
13. Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell
carcinoma of the penis: recommendations for follow-up based on a two-centre
analysis of 700 patients. Eur Urol 2008;54:161e8.
14. Falconer AD, Hirschowitz L, Weeks J, et al. The impact of improving outcomes
guidance on surgical management of vulval squamous cell cancer in southwest
England (1997-2002). BJOG 2007;114:391e7.
15. Wu X, Matanoski G, Chen VW, et al. Descriptive epidemiology of vaginal cancer
incidence and survival by race, ethnicity, and age in the United States. Cancer
2008;113:2873e82.
16. CancerHelp UK. Vaginal Cancer. Cancer Research UK. 2011. http://www.
cancerhelp.org.uk/type/vaginal-cancer/ (accessed May 2011).
17. Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal
carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol)
2004;16:530e5.
18. Ness RM, Holmes AM, Klein R, et al. Utility valuations for outcome states of
colorectal cancer. Am J Gastroenterol 1999;94:1650e7.
19. Janda M, Obermair A, Cella D, et al. Vulvar cancer patients’ quality of life:
a qualitative assessment. Int J Gynecol Cancer 2004;14:875e81.
20. Likes WM, Stegbauer C, Tillmanns T, et al. Correlates of sexual function following
vulvar excision. Gynecol Oncol 2007;105:600e3.
21. Maddineni SB, Lau MM, Sangar VK. Identifying the needs of penile cancer
sufferers: a systematic review of the quality of life, psychosexual and psychosocial
literature in penile cancer. BMC Urol 2009;9:8.
22. Murphy BA, Ridner S, Wells N, et al. Quality of life research in head and neck
cancer: a review of the current state of the science. Crit Rev Oncol Hematol
2007;62:251e67.
23. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients
after treatment with high-dose radiotherapy alone or in combination with cetuximab.
J Clin Oncol 2007;25:2191e7.
24. Fang FM, Tsai WL, Chien CY, et al. Changing quality of life in patients with advanced
head and neck cancer after primary radiotherapy or chemoradiation. Oncology
2005;68:405e13.
25. Pourel N, Peiffert D, Lartigau E, et al. Quality of life in long-term survivors of
oropharynx carcinoma. Int J Radiat Oncol Biol Phys 2002;54:742e51.
26. Dolan P. Valuing health-related quality of life. Issues and controversies.
Pharmacoeconomics 1999;15:119e27.
27. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the Economic
Evaluation of Health Care Programs. 3rd edn. Oxford: Oxford University Press, 2005.
28. Breetvelt IS, Van Dam FS. Underreporting by cancer patients: the case of response-
shift. Soc Sci Med 1991;32:981e7.
29. Beusterien KM, Szabo SM, Kotapati S, et al. Societal preference values for
advanced melanoma health states in the United Kingdom and Australia. Br J Cancer
2009;101:387e9.
30. Bernert S, Fernandez A, Haro JM, et al. Comparison of different valuation methods




Sex Transm Infect 2012;88:517–521. doi:10.1136/sextrans-2011-050161 521
 group.bmj.com on February 3, 2013 - Published by sti.bmj.comDownloaded from 
doi: 10.1136/sextrans-2011-050161
2012
 2012 88: 517-521 originally published online May 29,Sex Transm Infect
 
E Lynne Conway, K Chip Farmer, William J Lynch, et al.
 
population
cancer health states by the general 
Quality of life valuations of HPV-associated
 http://sti.bmj.com/content/88/7/517.full.html







Article cited in: 
 
 http://sti.bmj.com/content/88/7/517.full.html#ref-list-1




compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on February 3, 2013 - Published by sti.bmj.comDownloaded from 
Collections
Topic
 (267 articles)Vulvovaginal disorders   
 (8 articles)Urological cancer   
 (86 articles)Gynecological cancer   
 (95 articles)Vaccination / immunisation   
 (1779 articles)Drugs: infectious diseases   
 (11 articles)Ear, nose and throat/otolaryngology   
 (108 articles)Open access   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on February 3, 2013 - Published by sti.bmj.comDownloaded from 
